Avalon Pharmaceuticals doesn't mind if genes express themselves -- but they should know that anything they express can and will be used against them if they lead to cancer. The biopharmaceutical firm develops cancer therapeutics based on its AvalonRx platform, which identifies compounds that would be best suited to advance in clinical drug development. Lead product AVN944, an inhibitor of hematologic (leukemia, lymphoma, and myeloma) and solid tumor cancers, is an oral drug now in clinical trials. Avalon also has preclinical programs to develop inhibitors through partnerships with other drug companies. The company was acquired by Clinical Data in 2009.

AutoImmune Inc. is a biopharmaceutical company developing products to treat autoimmune and other cell-mediated inflammatory conditions. Several of these products are based on a biological mechanism known as oral tolerance, which provides tissue specific immunosuppression without toxicity or significant side effects.

Paddock Laboratories, Inc. company was founded in 1977 by Chairman Bruce Paddock. Paddock Laboratories, Inc. company develops and manufactures bioequivalent generic pharmaceuticals and OTC specialty products. Paddock's product line includes suppositories, diabetes treatments, topical powders, enemas, injectables, and dermatological offerings, as well as compounding bases and charcoal products. Its manufacturing facilities are located in Minneapolis, Minnesota. In addition to the US market, some of Paddock's products are sold in Europe and the Asia/Pacific region through distributors.

GeneFluidics, Inc. develops electrochemical sensor platform for molecular analysis. Its solutions perform bioassays with sensitivity to picogram/ml concentrations for immunoassays and femtomolar concentrations for genetic assays. The company’s products include sensor chip arrays; Proteus, a modular robotic system; and Asklepios, the multi-channel microfluidics cartidge system. Its products are used for human diagnostics, animal health, environmental monitoring, and blood banking applications. The company was incorporated in 2000 and is headquartered in Monterey Park, California.

China DongSheng International manufactures nutritional supplements and air purifiers. Founded in 1991 as PaperClip Imaging Software, the company's original business was document management software development. After a 2006 reverse merger with American Sunrise International (the holding company of China-based Jilin Dongsheng Weiye Science & Technology Development Co.), the company changed its name to China DongSheng International and shifted its focus to natural health supplements and purifiers. Now generating the majority of its revenues from its new lines, China DongSheng plans to spin off its PaperClip operations.

Cerus Corporation company was founded in 1991 and is based in Concord, California. Cerus Corporation, a biomedical products company, engages in the development and commercialization of the INTERCEPT Blood System. The company’s INTERCEPT system is designed to inactivate blood-borne pathogens in donated blood components intended for transfusion. It markets the INTERCEPT system for platelets and plasma primarily in Europe, the Russian Federation, and the Middle East. The company is also developing INTERCEPT Blood System for red blood cells or red blood cell system, which is designed to inactivate blood-borne pathogens in donated red blood cells for transfusion. It has collaboration agreements with Baxter International, Inc., BioOne Corporation, and Laboratorios Grifols S.A., as well as the United States Armed Forces.

AVEO Pharmaceuticals' models don't pout, strut, or even turn heads -- unless you're a cancer drug researcher. The biotech firm develops cancer models to uncover how genes mutate into tumors and how tumors progress through additional mutations. AVEO then builds genetic profiles of such tumors and applies them to antibody (protein) drug candidates in preclinical and clinical development to help predict actual human responses. In addition to its own pipeline of potential drugs, AVEO has partnered with other pharmaceutical developers to apply its Human Response Platform to their drug candidates.

Hana Biosciences, Inc. company was founded in 2002 and is based in South San Francisco, California. Hana Biosciences, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing products for the foundation of cancer care. The company develops Optisome encapsulated formulation product candidates and a supportive care product candidate. Optisomal encapsulation is a method of liposomal drug delivery, which is designed to increase tumor targeting and duration of exposure for cell-cycle specific anticancer agents. Its Optisome encapsulated formulation product candidates include Marqibo, a vincristine sulfate liposomes injection for the treatment of adult acute lymphoblastic leukemia and metastatic uveal melanoma; Brakiva, a topotecan liposomes injection for the treatment of solid tumors, including small cell lung cancer and ovarian cancer; and Alocrest, a vinorelbine liposomes injection, which is used in the treatment of non-small cell lung cancer. The company's supportive care product candidate comprises Menadione Topical Lotion, a novel supportive care product candidate for the prevention and/or treatment of the skin toxicities associated with the use of epidermal growth factor receptor inhibitors, which are used in the treatment of lung, colon, head and neck, and pancreatic cancer.

Halozyme Therapeutics, Inc. company was founded in 1998 and is based in San Diego, California. Halozyme Therapeutics, Inc. (Halozyme) is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix (Matrix) for the endocrinology, oncology, dermatology and drug delivery markets The Company's products are based on the property covering the family of human enzymes known as hyaluronidases. The Company has two marketed products: HYLENEX, a product used as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids, and Cumulase, a product used for in vitro fertilization (IVF). The Company has partnerships with F. Hoffmann-La Roche, Ltd and Hoffmann-La Roche, Inc. (Roche), to apply Enhanze Technology to Roche’s biological therapeutic compounds for up to 13 targets, and with Baxter Healthcare Corporation (Baxter), to apply Enhanze Technology to Baxter’s biological therapeutic compound, GAMMAGARD LIQUID.

Charles River Laboratories International, Inc. company was founded in 1947 and is headquartered in Wilmington, Massachusetts. Charles River Laboratories International, Inc. provides research models and laboratory animal support expertise to help its global partners advance their research and drug development efforts. The company offers a portfolio of services to support discovery and imaging, preclinical and early-phase clinical studies, and biopharmaceutical and endotoxin products and services for manufacturing and quality control. Its portfolio spans the entire research and drug development process, from IND consultation to discovery through market approval, allowing customized approaches to support both single-study or broad-based programs. Charles River Laboratories International serves pharmaceutical and biotechnology companies, as well as government agencies, hospitals, and academic institutions.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.